This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

Dr Michael Jarvis

Dr Michael Jarvis

Name:

Dr Michael Jarvis FBPhS

Organisation:

Abbvie, Inc.

Year elected:

2019

Affinity Group(s):

  • Drug Discovery, Development and Evaluation

Primary professional setting:

Industry

Mike has extensive experience in all phases of drug discovery research from target identification and validation through drug candidate selection and clinical development including Phase-II proof of concept studies and drug life-cycle management. He has effectively led multidisciplinary research teams to generate state-of-the-art scientific advances in pharmacology, molecular biology, neurophysiology and medicinal chemistry targeting multiple therapeutic areas. He has published more than 240 peer-reviewed papers (H-index = 65). In his current Medical Affairs role, he provides scientific and medical oversight of established therapies for epilepsy, pain and dyslipidemia as well as supporting late-stage development of novel therapies for cystic fibrosis. He is a former Editor-in-Chief of ASPET’s Journal of Pharmacology and Experimental Therapeutics and a past reviewing editor for the British Journal of Pharmacology. He is the current Deputy Editor of the ASPET/BPS/Wiley collaborative open access journal, Pharmacology Research & Perspectives.